A<unk>  is designed to prevent the symptoms and complications of<unk><unk>  infection in humans. As<unk><unk>  infection of pregnant women may result in congenital defects in the newborn, the vaccine will attempt to protect against congenital<unk>  syndrome during the current or any future outbreak. As of April 2019, no vaccines have been approved for clinical use, however a number of vaccines are currently in clinical trials. The goal of a<unk>  is to produce specific antibodies against the<unk><unk>  to prevent infection and severe disease. The challenges in developing a safe and effective vaccine include limiting side effects such as Guillain-Barré syndrome, a potential consequence of<unk><unk>  infection. Additionally, as dengue<unk>  is closely related to<unk><unk> , the vaccine needs to minimize the possibility of antibody-dependent enhancement of dengue<unk>  infection.
Zika virus vaccine
Japanese encephalitis vaccine
Malaria vaccine
Tick-borne encephalitis vaccine
Dengue vaccine
Ebola vaccine
Hantavirus vaccine
RVSV-ZEBOV vaccine